Evidence map›Paper›PMID 32910710›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.

David M Waterhouse, Edward B Garon, Jason Chandler, Michael McCleod, Maen Hussein, Robert Jotte, Leora Horn, Davey B Daniel, George Keogh, Ben Creelan and 13 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Current and future immunotherapies for NSCLC.Journal of hematology & oncology · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

David M WaterhouseThe US Oncology Network/Oncology Hematology Care, Cincinnati, OH.
Edward B GaronDavid Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network, Los Angeles, CA.
Jason ChandlerWest Cancer Center, Memphis, TN.
Michael McCleodSarah Cannon Research Institute/Florida Cancer Specialists, Cape Coral, FL.
Maen HusseinSarah Cannon Research Institute/Florida Cancer Specialists, The Villages, FL.
Robert JotteThe US Oncology Network/Rocky Mountain Cancer Centers, Denver, CO.
Leora HornVanderbilt University Medical Center, Nashville, TN.
Davey B DanielSarah Cannon Research Institute/Tennessee Oncology, Chattanooga, TN.
George KeoghCharleston Oncology, Charleston, SC.
Ben CreelanMoffitt Cancer Center, Tampa, FL.
Lawrence H EinhornSimon Cancer Center, Indiana University, Indianapolis, IN.
Justin BakerJackson Oncology Associates, Jackson, MS.
Samer KasbariSoutheastern Medical Oncology Center, Goldsboro, NC.
Petros NikolinakosHematology and Medical Oncology, University Cancer and Blood Center, LLC, Athens, GA.
Sunil BabuFort Wayne Medical Oncology and Hematology, Fort Wayne, IN.
Felix CoutureCISSS Chaudiéere-Appalaches, Levis, Quebec, Canada.
Natasha B LeighlDepartment of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Craig ReynoldsSarah Cannon Research Institute/Florida Cancer Specialists, Ocala, FL.
George BlumenscheinDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Vijay GunugantiTexas Oncology, San Antonio, TX.
Ang LiBristol Myers Squibb Company, Princeton, NJ.
Nivedita AanurBristol Myers Squibb Company, Princeton, NJ.
David R SpigelSarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLimited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab.

methodsPatients with previously treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks). Those still receiving treatment at 1 year, including patients perceived to be deriving benefit despite radiographic progression, were randomly assigned to continue nivolumab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-study retreatment after disease progression (1-year fixed duration).

resultsOf 1,428 patients treated, 252 were randomly assigned to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). Of these, 89 and 85 patients in the continuous and 1-year fixed-duration arms, respectively, had not progressed (progression-free survival [PFS] population). With minimum post-random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixed-duration treatment (PFS population: 24.7 months

conclusionTo our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDisease ProgressionDrug Administration ScheduleFemaleHumansImmune Checkpoint InhibitorsLung NeoplasmsMaleMiddle AgedNivolumabImmune Checkpoint InhibitorsNivolumab

Identifiers

PMID32910710
PMCPMC7676888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.